Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.
ACS Med Chem Lett
; 3(3): 216-21, 2012 Mar 08.
Article
in En
| MEDLINE
| ID: mdl-24900457
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
ACS Med Chem Lett
Year:
2012
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Estados Unidos